1. Home
  2. SDGR vs GSBD Comparison

SDGR vs GSBD Comparison

Compare SDGR & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SDGR
  • GSBD
  • Stock Information
  • Founded
  • SDGR 1990
  • GSBD 2012
  • Country
  • SDGR United States
  • GSBD United States
  • Employees
  • SDGR N/A
  • GSBD N/A
  • Industry
  • SDGR Biotechnology: Pharmaceutical Preparations
  • GSBD Finance: Consumer Services
  • Sector
  • SDGR Health Care
  • GSBD Finance
  • Exchange
  • SDGR Nasdaq
  • GSBD Nasdaq
  • Market Cap
  • SDGR 1.5B
  • GSBD 1.4B
  • IPO Year
  • SDGR 2020
  • GSBD N/A
  • Fundamental
  • Price
  • SDGR $20.56
  • GSBD $11.31
  • Analyst Decision
  • SDGR Buy
  • GSBD Sell
  • Analyst Count
  • SDGR 5
  • GSBD 2
  • Target Price
  • SDGR $32.80
  • GSBD $12.00
  • AVG Volume (30 Days)
  • SDGR 1.2M
  • GSBD 622.5K
  • Earning Date
  • SDGR 07-30-2025
  • GSBD 08-07-2025
  • Dividend Yield
  • SDGR N/A
  • GSBD 11.37%
  • EPS Growth
  • SDGR N/A
  • GSBD N/A
  • EPS
  • SDGR N/A
  • GSBD 0.45
  • Revenue
  • SDGR $230,492,000.00
  • GSBD $419,771,000.00
  • Revenue This Year
  • SDGR $24.44
  • GSBD N/A
  • Revenue Next Year
  • SDGR $22.17
  • GSBD N/A
  • P/E Ratio
  • SDGR N/A
  • GSBD $25.23
  • Revenue Growth
  • SDGR 22.29
  • GSBD N/A
  • 52 Week Low
  • SDGR $16.60
  • GSBD $9.51
  • 52 Week High
  • SDGR $28.47
  • GSBD $15.64
  • Technical
  • Relative Strength Index (RSI)
  • SDGR 38.35
  • GSBD 43.45
  • Support Level
  • SDGR $20.04
  • GSBD $11.33
  • Resistance Level
  • SDGR $20.88
  • GSBD $11.79
  • Average True Range (ATR)
  • SDGR 1.24
  • GSBD 0.16
  • MACD
  • SDGR -0.28
  • GSBD -0.03
  • Stochastic Oscillator
  • SDGR 9.51
  • GSBD 6.45

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company's origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

Share on Social Networks: